Age: 14.0
Sex: M
Vaccine: COVID19, FLU4, HEP, IPV, MMRV
Symptoms: Chest pain, Electrocardiogram, Headache, Laboratory test, Pericarditis
Clinical narrative: pericarditis; chest pain; headache; Initial information received from country on 18-Dec-2023 regarding an unsolicited valid serious Courtesy case received from a consumer/non-hcp (non-healthcare professional).  This case involves 14 years old male patient who had pericarditis, chest pain and headache after receiving covid-19 vaccine PROT. SUBUNIT (NVX COV 2373) (Novavax Covid-19 Vaccine); Hepatitis B vaccine RHBSAG (YEAST) (Recombivax HB); measles vaccine live (ENDERS-EDMONSTON), mumps vaccine live (jeryl lynn), rubella vaccine live (WISTAR RA 27/3), varicella zoster vaccine live (OKA/MERCK) (Proquad);  IPV (VERO) [IPOL] and influenza quadrival A-B vaccine [Fluzone Quadrivalent].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. At the time of the event, the patient had ongoing Back pain and Asthma. The individual had no known allergies.  Concomitant medications included SAlbutamol (Albuterol [Salbutamol]); Salicylic Acid (Compound W); and Sodium Fluoride (Denta 5000 Plus).  On 20-Oct-2023, the patient received a dose 1 of suspect influenza quadrival A-B vaccine Suspension for injection (lot 72423) via intramuscular route in the right arm; also received a dose 2 of suspect Recombivax HB not produced by Sanofi Pasteur (with an unknown formulation) (lot W035042) via intramuscular route in the right arm; received a dose 2 of suspect Proquad not produced by Sanofi Pasteur  (with an unknown formulation) lot V014623 via intramuscular route in the left arm and  received a dose 2 of suspect IPV (VERO) Suspension for injection (lot W1C751M) via intramuscular route in the left arm (with an unknown strength and expiry date) for prophylactic vaccination (Immunisation).  On 20-Oct-2023, the patient received a dose 2 of suspect novavax covid-19 vaccine Adjuvanted (2023-2024 Formula) not produced by Sanofi Pasteur (with an unknown formulation, strength and expiry date) at a dose of 0.5 ml (lot 5433MF001) via intramuscular route in the right arm for COVID-19 vaccination (COVID-19 immunisation).  On 29-OCT-2023 the patient developed pericarditis, chest pain and headache 9 days following the administration of influenza quadrival A-B vaccine, IPV (VERO), Recombivax HB, Proquad and novavax covid-19 vaccine.   Reportedly, Sudden onset chest pain and headache, then the individual went to the emergency room, where he was diagnosed with pericarditis. Currently seeing cardiology. The individual had an office visit on an unreported date.  Relevant laboratory test results included: Electrocardiogram - On 29-Oct-2023:  [no results reported] Laboratory test - On 29-Oct-2023:  [no results reported] Troponin - On 29-Oct-2023:  [no results reported]  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the events.  At time of reporting, the outcome was Unknown for all the events.  Seriousness criteria: medically significant for the event pericarditis.; Sender's Comments: Sanofi company comment dated 26-DEC-2023: This case involves 14 years old male patient who had pericarditis, chest pain and headache after receiving covid-19 vaccine PROT. SUBUNIT (NVX COV 2373) (Novavax Covid-19 Vaccine); Hepatitis B vaccine RHBSAG (YEAST) (Recombivax HB); measles vaccine live (ENDERS-EDMONSTON), mumps vaccine live (jeryl lynn), rubella vaccine live (WISTAR RA 27/3), varicella zoster vaccine live (OKA/MERCK) (Proquad);  IPV (VERO) [IPOL] and influenza quadrival A-B vaccine [Fluzone Quadrivalent]. Further information regarding concomitant medication, and tolerance, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, the role of the suspect vaccine cannot be assessed. Furthermore, medical history of the patient is a confounding factor.